Login
Evidence Feed
About
Conferences
New
Diagnostics
New
Top genes
New
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
CANCER:
Follicular Lymphoma
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related cancers:
‹
Non-Hodgkin’s Lymphoma (888
)
Diffuse Large B Cell Lymphoma (310
)
Mantle Cell Lymphoma (105
)
Small Lymphocytic Lymphoma (99
)
T Cell Non-Hodgkin Lymphoma (90
)
Lymphoplasmacytic Lymphoma (63
)
Peripheral T-cell Lymphoma (54
)
Marginal Zone Lymphoma (34
)
Burkitt Lymphoma (18
)
Cutaneous T-cell Lymphoma (13
)
Mediastinal B Cell Lymphoma (8
)
Non-Hodgkin’s Lymphoma (888
)
Diffuse Large B Cell Lymphoma (310
)
Mantle Cell Lymphoma (105
)
Small Lymphocytic Lymphoma (99
)
T Cell Non-Hodgkin Lymphoma (90
)
Lymphoplasmacytic Lymphoma (63
)
Peripheral T-cell Lymphoma (54
)
Marginal Zone Lymphoma (34
)
Burkitt Lymphoma (18
)
Cutaneous T-cell Lymphoma (13
)
Mediastinal B Cell Lymphoma (8
)
›
Associations
(79)
News
Twitter
Trials
Reset Filters
VERI cancer hierarchy
x
x
x
x
No biomarker
Follicular Lymphoma
No biomarker
Follicular Lymphoma
mosunetuzumab
Sensitive: A1 - Approval
NCCN - 1 week (New A2)
mosunetuzumab
Sensitive
:
A1
NCCN - 1wk
mosunetuzumab
Sensitive: A1 - Approval
NCCN - 1 week
mosunetuzumab
Sensitive
:
A1
NCCN - 1 week - (New A2)
No biomarker
Follicular Lymphoma
No biomarker
Follicular Lymphoma
tazemetostat
Sensitive: A2 - Guideline
NCCN - 1 week (New A2)
tazemetostat
Sensitive
:
A2
NCCN - 1wk
tazemetostat
Sensitive: A2 - Guideline
NCCN - 1 week
tazemetostat
Sensitive
:
A2
NCCN - 1 week - (New A2)
No biomarker
Follicular Lymphoma
No biomarker
Follicular Lymphoma
axicabtagene ciloleucel
Sensitive: A1 - Approval
axicabtagene ciloleucel
Sensitive
:
A1
axicabtagene ciloleucel
Sensitive: A1 - Approval
axicabtagene ciloleucel
Sensitive
:
A1
No biomarker
Follicular Lymphoma
No biomarker
Follicular Lymphoma
rituximab + lenalidomide
Sensitive: A1 - Approval
rituximab + lenalidomide
Sensitive
:
A1
rituximab + lenalidomide
Sensitive: A1 - Approval
rituximab + lenalidomide
Sensitive
:
A1
No biomarker
Follicular Lymphoma
No biomarker
Follicular Lymphoma
rituximab-abbs
Sensitive: A1 - Approval
rituximab-abbs
Sensitive
:
A1
rituximab-abbs
Sensitive: A1 - Approval
rituximab-abbs
Sensitive
:
A1
No biomarker
Follicular Lymphoma
No biomarker
Follicular Lymphoma
Rixathon (rituximab biosimilar)
Sensitive: A1 - Approval
Rixathon (rituximab biosimilar)
Sensitive
:
A1
Rixathon (rituximab biosimilar)
Sensitive: A1 - Approval
Rixathon (rituximab biosimilar)
Sensitive
:
A1
No biomarker
Follicular Lymphoma
No biomarker
Follicular Lymphoma
rituximab-pvvr
Sensitive: A1 - Approval
rituximab-pvvr
Sensitive
:
A1
rituximab-pvvr
Sensitive: A1 - Approval
rituximab-pvvr
Sensitive
:
A1
No biomarker
Follicular Lymphoma
No biomarker
Follicular Lymphoma
obinutuzumab
Sensitive: A1 - Approval
obinutuzumab
Sensitive
:
A1
obinutuzumab
Sensitive: A1 - Approval
obinutuzumab
Sensitive
:
A1
No biomarker
Follicular Lymphoma
No biomarker
Follicular Lymphoma
rituximab
Sensitive: A1 - Approval
rituximab
Sensitive
:
A1
rituximab
Sensitive: A1 - Approval
rituximab
Sensitive
:
A1
CD20 positive
Follicular Lymphoma
CD20 positive
Follicular Lymphoma
rituximab + ibritumomab tiuxetan
Sensitive: A1 - Approval
rituximab + ibritumomab tiuxetan
Sensitive
:
A1
rituximab + ibritumomab tiuxetan
Sensitive: A1 - Approval
rituximab + ibritumomab tiuxetan
Sensitive
:
A1
No biomarker
Follicular Lymphoma
No biomarker
Follicular Lymphoma
ibritumomab tiuxetan
Sensitive: A1 - Approval
ibritumomab tiuxetan
Sensitive
:
A1
ibritumomab tiuxetan
Sensitive: A1 - Approval
ibritumomab tiuxetan
Sensitive
:
A1
No biomarker
Follicular Lymphoma
No biomarker
Follicular Lymphoma
idelalisib
Sensitive: A1 - Approval
idelalisib
Sensitive
:
A1
idelalisib
Sensitive: A1 - Approval
idelalisib
Sensitive
:
A1
No biomarker
Follicular Lymphoma
No biomarker
Follicular Lymphoma
duvelisib
Sensitive: A1 - Approval
duvelisib
Sensitive
:
A1
duvelisib
Sensitive: A1 - Approval
duvelisib
Sensitive
:
A1
EZH2 wild-type
Follicular Lymphoma
EZH2 wild-type
Follicular Lymphoma
tazemetostat
Sensitive: A1 - Approval
tazemetostat
Sensitive
:
A1
tazemetostat
Sensitive: A1 - Approval
tazemetostat
Sensitive
:
A1
EZH2 mutation
Follicular Lymphoma
EZH2 mutation
Follicular Lymphoma
tazemetostat
Sensitive: A1 - Approval
tazemetostat
Sensitive
:
A1
tazemetostat
Sensitive: A1 - Approval
tazemetostat
Sensitive
:
A1
No biomarker
Follicular Lymphoma
No biomarker
Follicular Lymphoma
copanlisib
Sensitive: A1 - Approval
copanlisib
Sensitive
:
A1
copanlisib
Sensitive: A1 - Approval
copanlisib
Sensitive
:
A1
No biomarker
Follicular Lymphoma
No biomarker
Follicular Lymphoma
umbralisib
Sensitive: A1 - Approval
umbralisib
Sensitive
:
A1
umbralisib
Sensitive: A1 - Approval
umbralisib
Sensitive
:
A1
No biomarker
Follicular Lymphoma
No biomarker
Follicular Lymphoma
lisocabtagene maraleucel
Sensitive: A1 - Approval
lisocabtagene maraleucel
Sensitive
:
A1
lisocabtagene maraleucel
Sensitive: A1 - Approval
lisocabtagene maraleucel
Sensitive
:
A1
No biomarker
Follicular Lymphoma
No biomarker
Follicular Lymphoma
tisagenlecleucel-T
Sensitive: A1 - Approval
tisagenlecleucel-T
Sensitive
:
A1
tisagenlecleucel-T
Sensitive: A1 - Approval
tisagenlecleucel-T
Sensitive
:
A1
CD20 positive
Follicular Lymphoma
CD20 positive
Follicular Lymphoma
rituximab-pvvr
Sensitive: A1 - Approval
rituximab-pvvr
Sensitive
:
A1
rituximab-pvvr
Sensitive: A1 - Approval
rituximab-pvvr
Sensitive
:
A1
No biomarker
Follicular Lymphoma
No biomarker
Follicular Lymphoma
rituximab/hyaluronidase
Sensitive: A1 - Approval
rituximab / hyaluronidase
Sensitive
:
A1
rituximab/hyaluronidase
Sensitive: A1 - Approval
rituximab / hyaluronidase
Sensitive
:
A1
No biomarker
Follicular Lymphoma
No biomarker
Follicular Lymphoma
R-CHOP
Sensitive: A2 - Guideline
R-CHOP
Sensitive
:
A2
R-CHOP
Sensitive: A2 - Guideline
R-CHOP
Sensitive
:
A2
No biomarker
Follicular Lymphoma
No biomarker
Follicular Lymphoma
R-CVP
Sensitive: A2 - Guideline
R-CVP
Sensitive
:
A2
R-CVP
Sensitive: A2 - Guideline
R-CVP
Sensitive
:
A2
No biomarker
Follicular Lymphoma
No biomarker
Follicular Lymphoma
rituximab + obinutuzumab
Sensitive: A2 - Guideline
rituximab + obinutuzumab
Sensitive
:
A2
rituximab + obinutuzumab
Sensitive: A2 - Guideline
rituximab + obinutuzumab
Sensitive
:
A2
No biomarker
Follicular Lymphoma
No biomarker
Follicular Lymphoma
lenalidomide
Sensitive: A2 - Guideline
lenalidomide
Sensitive
:
A2
lenalidomide
Sensitive: A2 - Guideline
lenalidomide
Sensitive
:
A2
No biomarker
Follicular Lymphoma
No biomarker
Follicular Lymphoma
chlorambucil
Sensitive: A2 - Guideline
chlorambucil
Sensitive
:
A2
chlorambucil
Sensitive: A2 - Guideline
chlorambucil
Sensitive
:
A2
No biomarker
Follicular Lymphoma
No biomarker
Follicular Lymphoma
lenalidomide + obinutuzumab
Sensitive: A2 - Guideline
lenalidomide + obinutuzumab
Sensitive
:
A2
lenalidomide + obinutuzumab
Sensitive: A2 - Guideline
lenalidomide + obinutuzumab
Sensitive
:
A2
No biomarker
Follicular Lymphoma
No biomarker
Follicular Lymphoma
cyclophosphamide
Sensitive: A2 - Guideline
cyclophosphamide
Sensitive
:
A2
cyclophosphamide
Sensitive: A2 - Guideline
cyclophosphamide
Sensitive
:
A2
No biomarker
Follicular Lymphoma
No biomarker
Follicular Lymphoma
G-CHOP
Sensitive: A2 - Guideline
G-CHOP
Sensitive
:
A2
G-CHOP
Sensitive: A2 - Guideline
G-CHOP
Sensitive
:
A2
No biomarker
Follicular Lymphoma
No biomarker
Follicular Lymphoma
GVD
Sensitive: A2 - Guideline
GVD
Sensitive
:
A2
GVD
Sensitive: A2 - Guideline
GVD
Sensitive
:
A2
No biomarker
Follicular Lymphoma
No biomarker
Follicular Lymphoma
carboplatin + cytarabine + dexamethasone
Sensitive: A2 - Guideline
carboplatin + cytarabine + dexamethasone
Sensitive
:
A2
carboplatin + cytarabine + dexamethasone
Sensitive: A2 - Guideline
carboplatin + cytarabine + dexamethasone
Sensitive
:
A2
No biomarker
Follicular Lymphoma
No biomarker
Follicular Lymphoma
DHAX
Sensitive: A2 - Guideline
DHAX
Sensitive
:
A2
DHAX
Sensitive: A2 - Guideline
DHAX
Sensitive
:
A2
No biomarker
Follicular Lymphoma
No biomarker
Follicular Lymphoma
DHAP
Sensitive: A2 - Guideline
DHAP
Sensitive
:
A2
DHAP
Sensitive: A2 - Guideline
DHAP
Sensitive
:
A2
No biomarker
Follicular Lymphoma
No biomarker
Follicular Lymphoma
ruxolitinib
Sensitive: A2 - Guideline
ruxolitinib
Sensitive
:
A2
ruxolitinib
Sensitive: A2 - Guideline
ruxolitinib
Sensitive
:
A2
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login